Voyager Therapeutics’ (VYGR) “Buy” Rating Reaffirmed at HC Wainwright

Voyager Therapeutics (NASDAQ:VYGR)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research report issued to clients and investors on Thursday,Benzinga reports. They presently have a $30.00 price target on the stock.

VYGR has been the topic of several other research reports. Wells Fargo & Company set a $10.00 price objective on shares of Voyager Therapeutics and gave the company an “overweight” rating in a report on Wednesday. StockNews.com cut shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Cantor Fitzgerald reissued an “overweight” rating on shares of Voyager Therapeutics in a research report on Wednesday. Canaccord Genuity Group reaffirmed a “buy” rating and set a $14.00 price objective on shares of Voyager Therapeutics in a report on Thursday, November 14th. Finally, Citigroup started coverage on shares of Voyager Therapeutics in a research report on Monday, December 2nd. They set a “buy” rating and a $12.00 price target on the stock. One analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Voyager Therapeutics currently has an average rating of “Buy” and an average target price of $15.08.

Voyager Therapeutics Price Performance

NASDAQ VYGR opened at $4.06 on Thursday. Voyager Therapeutics has a one year low of $3.56 and a one year high of $10.66. The business has a 50 day simple moving average of $4.95 and a 200 day simple moving average of $5.87. The stock has a market capitalization of $221.78 million, a P/E ratio of 5.72 and a beta of 0.99.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings data on Tuesday, March 11th. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.24). The company had revenue of $4.39 million during the quarter, compared to the consensus estimate of $16.58 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same quarter in the prior year, the firm earned $1.25 EPS. Equities analysts expect that Voyager Therapeutics will post -0.91 earnings per share for the current year.

Insiders Place Their Bets

In other Voyager Therapeutics news, COO Robin Swartz sold 6,500 shares of the stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $5.65, for a total transaction of $36,725.00. Following the completion of the transaction, the chief operating officer now owns 112,328 shares of the company’s stock, valued at $634,653.20. This represents a 5.47 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Over the last ninety days, insiders have sold 10,778 shares of company stock worth $58,548. Company insiders own 4.53% of the company’s stock.

Institutional Trading of Voyager Therapeutics

Several institutional investors have recently added to or reduced their stakes in VYGR. Cubist Systematic Strategies LLC purchased a new position in shares of Voyager Therapeutics during the fourth quarter valued at $29,000. Tower Research Capital LLC TRC boosted its holdings in Voyager Therapeutics by 133.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company’s stock worth $31,000 after acquiring an additional 3,077 shares in the last quarter. Picton Mahoney Asset Management grew its position in Voyager Therapeutics by 71.1% during the 4th quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company’s stock worth $33,000 after purchasing an additional 2,444 shares during the last quarter. Oxford Asset Management LLP purchased a new stake in Voyager Therapeutics during the 4th quarter valued at about $60,000. Finally, Intech Investment Management LLC acquired a new stake in shares of Voyager Therapeutics during the third quarter worth about $74,000. Institutional investors own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.